Research Communication

Expression of TNF-α and Related Signaling Molecules in the Peripheral Blood Mononuclear Cells of Rheumatoid Arthritis Patients

Sunil Kumar Raghav, Bhawna Gupta, Charu Agrawal, Ved P. Chaturvedi, and Hasi R. Das

1 Institute of Genomics and Integrative Biology, Delhi University Campus, Mall Road, Delhi 110 007, India
2 Department of Rheumatology, Research and Referral, Army Hospital, New Delhi 110 010, India

Received 4 January 2006; Accepted 11 January 2006

We examined the role of tumor necrosis factor (TNF-α) and its related signaling intermediates leading to apoptosis/proliferation in the peripheral blood mononuclear cells (PBMCs) of RA patients. The constitutive expression of mRNA for TNF-α receptors (TNFR-I and TNFR-II) and the adapter molecules, such as the TNF receptor-associated death domain protein (TRADD), Fas-associated death domain protein (FADD), receptor interacting protein (RIP), and TNF receptor-associated factor 2 (TRAF-2) were analyzed by reverse transcriptase-PCR (RT-PCR) in PBMCs from control and RA cases. PBMCs of RA patients showed a significant increase in TNF-α and TNFR-I expression as compared with that from control subjects along with significantly increased constitutive expression of TRADD, RIP, and TRAF-2 mRNA. There was a decrease in expression of FADD in RA patients, but the difference was not significant as compared to controls. These data suggested enhanced signaling by the TNFR-I-TRADD-RIP-TRAF-2 pathway and suppressed signaling by the TNFR-I-TRADD-FADD pathway in PBMCs of RA patients. However, the regulatory mechanisms for TNF-α induced signaling may not be explained only by these pathways.

INTRODUCTION

Abnormal proliferation and/or persistence of synoviocytes and inflammatory cells has long been described in inflammatory arthritis conditions, but only recently substantial attention has been drawn to the relevance of abnormal apoptotic processes in disease pathogenesis and treatment [1]. Rheumatoid arthritis (RA) is a chronic inflammatory disorder with autoimmune features that affects approximately 1% of the world’s population. It is characterized by inflammation of synovial tissue and the formation of rheumatoid pannus, which is capable of eroding adjacent cartilage and bone causing subsequent joint destruction. Although the precise etiology of the disease is unknown, genetic and environmental factors seem to be involved in its pathogenesis [2]. Previous studies have indicated that the relative risk of developing the disease in siblings of affected individuals (λs) is 2–17 times higher as compared to the general population, suggesting the importance of genetic factors in rheumatoid arthritis [3]. Recently we reported an association of mannose binding lectin gene polymorphisms with the occurrence and disease progression [4]. The association of TNF-α microsatellite with susceptibility and progression of RA in our study population was found to be distinct from other populations [5].

A broad array of macrophage and fibroblast cytokines, including IL-1, IL-6, IL-15, IL-18, tumor necrosis factor (TNF-α), granulocyte-macrophage colony-stimulating factor (GM-CSF), various chemokines, and many others, is produced by rheumatoid synovium. Increased hyperplasia of the synovial membrane imposed by these proinflammatory cytokines has been suggested to play a crucial role in disease progression [6]. In rheumatoid arthritis, joint pathology has been shown to be associated with high IL1-β and TNF-α production and TNF antagonists have proven to be the most efficient therapy for RA thus far [6, 7].

TNF-α, a potent proinflammatory cytokine, is known to regulate cell survival, death, and/or growth depending upon the cell types [7]. The cytotoxic pathway involves interaction of death domain-containing adapter molecules and caspases leading to apoptosis, whereas the cell-protective pathway involves activation of transcription factors, including NF-kB [8]. TNF-α transduces its signals by binding with TNF receptors, TNFR-I and TNFR-II (Figure 1). These two receptors differ from each other, only by the presence of a
conserved motif in the cytoplasmic tail called the death domain [9]. TNFR-I mediates most of the biological properties of TNF-α, such as programmed cell death and activation of NF-kB. Upon activation, the death domain serves as a docking site for the death domain-containing adaptor proteins such as TRADD (TNFR associated death domain) through homotypic death domain interaction [10]. The recruitment of caspase-8 or -10 via the complex of TRADD and FADD (Fas-associated death domain) leads to the activation of a caspase cascade resulting in apoptosis [8, 9]. Once TRADD binds to the TNFR-I, it can also lead to the recruitment of RIP (receptor interacting protein) and TRAF-2 (TNF receptor-associated factor 2). RIP is a death domain-containing kinase that is crucial for NF-kB activation [9]. TNFR-II lacks the death domain but the intracellular domain of this receptor contains a consensus motif that allows binding to TRAF-2 [11]. TRAF-2 activates both NF-kB and JNK (cJun N-terminal kinase) and mediates its antiapoptotic effect [12]. Therefore, TNFR-II is involved in the antiapoptotic effect of TNF-α, whereas TNFR-I involves both apoptotic and antiapoptotic signaling [8]. NF-kB has been implicated in linking inflammatory responses to an anti-inflammatory pathway [13]. NF-kB is a ubiquitous transcription factor that can be activated by proinflammatory agents, such as TNF-α, IL-1β, LPS, oxidative stress [14]. In quiescent cells, NF-kB is sequestered in the cytoplasm by a set of inhibitory molecules including I-kB. Upon stimulation by any proinflammatory molecule the I-kB undergoes signal-induced phosphorylation and subsequent degradation. Once I-kB undergoes degradation, NF-kB translocates inside the nucleus and regulates the transcription of various inflammatory regulatory molecules [9].

In aged humans, the role of TNF-α induced apoptosis in decrease of T cells was examined by the expression of receptors for TNF-α by peripheral blood lymphocytes [15]. Increased constitutive expression of TNFR-I and TRADD and decreased expression of TNFR-II and TRAF-2 were observed in lymphocytes from aged as compared with young controls. These data suggest that increased TNF-α induced apoptosis plays a role in T-cell deficiency associated with human aging.

TNF-α was reported to be present at high concentrations in the blood and synovial fluid of RA patients. Therefore, differential expression and selective usage of TNF receptors may also work as a switch for TNF-α mediated signaling pathways on peripheral blood mononuclear cells (PBMCs) of RA patients. An increased expression of TNFR-II as compared to TNFR-I was also observed in synoviocytes as compared to peripheral blood mononuclear cells [9].

This study was designed to investigate the downstream signaling pathways of TNF-α in the PBMCs of RA patients. Expression of TNF receptors (TNFR-I and TNFR-II), TRADD, FADD, RIP, and TRAF-2 were analyzed to understand the mechanisms controlling apoptosis and proliferation in PBMCs of RA patients.

**MATERIALS AND METHODS**

**Patients and controls**

Blood samples from 27 patients diagnosed with rheumatoid arthritis were collected at the Out-Patient Department of Rheumatology, Army Hospital, Research and Referral, New Delhi, India, after a thorough investigation by the rheumatologist. All patients fulfilled the American College of Rheumatology classification criteria for the disease. The patients were diagnosed under the supervision of the rheumatologists using their medical records stating the disease duration, duration of morning stiffness, presence of extra-articular manifestations, presence of bone deformities, rheumatoid factor, and acute phase response (erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)). The disease activity score using DAS-28 [16] disease score calculator was calculated on the basis of the number of tender joints involved, number of swollen joints, ESR, and visual analogue score (VAS) for general health as subjectively estimated by the patients. The patients had an active form of the disease but none of them were put on any disease modifying antirheumatic drugs (DMARDs). Informed consent was obtained from each patient and normal individual. Both the control and case individuals were age, sex, and ethnicity matched. Age in the control group was 40 ± 5 years and for the RA patients was 45 ± 6 years. There were 15 females and 12 males in our cohort of RA patients. The procedures followed were in accord with the ethical standards established by the ethics committee of the Institute and the Army Hospital. Samples from 30 healthy individuals served as controls.

The blood samples were collected in the sterile vacutainers with ACD-A buffer (Greiner Bio-One GmbH). Peripheral blood mononuclear cells (PBMCs) were immediately isolated from the blood samples using Histopaque-1077 (Sigma Chemicals, USA) by vendor recommended protocol. The PBMC samples were stored at −80°C without any freeze thawing till the samples were further processed for RNA isolation.

---

**Figure 1:** An overview of the TNF-α signaling pathway leading to apoptosis or proliferation of the cells.
First-strand cDNA synthesis and gene specific polymerase chain reaction (PCR)

Total RNA was isolated from frozen PBMC samples by EZ-RNA isolation kit (Biological Industries) using vendor recommended protocol. The isolated RNA was dissolved in DEPC (diethyl pyrocarbonate, Sigma Chemicals, USA) treated deionized water and quantified. Two micrograms of the total RNA were used to initiate the first-strand cDNA synthesis using Advantage RT-for-PCR Kit (BD Clontech) by following vendor’s recommended procedure. Control RNA and the primers for G3PDH are included in the kit and were used to validate the quality of cDNA synthesized for each reaction. Gene specific primers were designed using the DNASTAR software. Primer sequences specific for the TNF-α mediated signaling genes used for the amplification of cDNA prepared from PBMCs from RA patients revealed a stronger expression of TNF-α and TNF-α mediated signaling genes involved in the TNF-α mediated signaling pathway.

We analyzed the constitutive expression of the genes that are involved in TNF-α mediated signaling in PBMCs of 30 normal healthy controls and 27 RA patients. We observed the following significant differences in the gene expression profile of the RA patients in comparison to the healthy controls.

Expression of TNF-α, TNFR-I, and TNFR-II genes

PBMCs from RA patients revealed a stronger expression of TNF-α and TNFR-I mRNA than those from the controls (Figure 2). There was a statistically significant difference (P < 0) between the expression of TNF-α in the RA patients (mean ± SD = 1.607 ± 0.39) with the healthy controls (mean ± SD = 1.0215 ± 0.224). An increase (P < .0003) in the expression of TNFR-I was observed in the RA patients (mean ± SD = 2.1289 ± 0.8117) as compared to the healthy controls (1.398 ± 0.5428, mean ± SD, Figure 2). However, we did not find an altered expression of TNFR-II gene in the PBMCs of the controls/cases in our cohort. The level of the gene expression in the controls (mean ± SD = 1 ± 0) was similar to that in the RA patients (mean ± SD = 1 ± 0) without any statistical significance (P = .692).

Statistical analysis

All data presented represent the mean and standard error (SE) for n determinations. Data analyses were performed using the World Wide Web available software. The density of PCR product for each sample was measured and the relative density mean (the value of the intensity of PCR product divided by the intensity for G3PDH) was calculated. All pairwise multiple comparisons were made using the Student t-test. The two tailed P values equal to or less than 0.05 were considered significant. Means ± SD (standard deviation) of the raw data used for normalization is presented in the results.

RESULTS

Expression of genes involved in the TNF-α mediated signaling pathway

We analyzed the constitutive expression of the genes that are involved in TNF-α mediated signaling in PBMCs of 30 normal healthy controls and 27 RA patients. We observed the following significant differences in the gene expression profile of the RA patients in comparison to the healthy controls.

Expression of TNF-α, TNFR-I, and TNFR-II genes

PBMCs from RA patients revealed a stronger expression of TNF-α and TNFR-I mRNA than those from the controls (Figure 2). There was a statistically significant difference (P < 0) between the expression of TNF-α in the RA patients (mean ± SD = 1.607 ± 0.39) with the healthy controls (mean ± SD = 1.0215 ± 0.224). An increase (P < .0003) in the expression of TNFR-I was observed in the RA patients (mean ± SD = 2.1289 ± 0.8117) as compared to the healthy controls (1.398 ± 0.5428, mean ± SD, Figure 2). However, we did not find an altered expression of TNFR-II gene in the PBMCs of the controls/cases in our cohort. The level of the gene expression in the controls (mean ± SD = 1 ± 0) was similar to that in the RA patients (mean ± SD = 1 ± 0) without any statistical significance (P = .692).

Statistical analysis

All data presented represent the mean and standard error (SE) for n determinations. Data analyses were performed using the World Wide Web available software. The density of PCR product for each sample was measured and the relative density mean (the value of the intensity of PCR product divided by the intensity for G3PDH) was calculated. All pairwise multiple comparisons were made using the Student t-test. The two tailed P values equal to or less than 0.05 were considered significant. Means ± SD (standard deviation) of the raw data used for normalization is presented in the results.

RESULTS

Expression of genes involved in the TNF-α mediated signaling pathway

We analyzed the constitutive expression of the genes that are involved in TNF-α mediated signaling in PBMCs of 30 normal healthy controls and 27 RA patients. We observed the following significant differences in the gene expression profile of the RA patients in comparison to the healthy controls.

Expression of TNF-α, TNFR-I, and TNFR-II genes

PBMCs from RA patients revealed a stronger expression of TNF-α and TNFR-I mRNA than those from the controls (Figure 2). There was a statistically significant difference (P < 0) between the expression of TNF-α in the RA patients (mean ± SD = 1.607 ± 0.39) with the healthy controls (mean ± SD = 1.0215 ± 0.224). An increase (P < .0003) in the expression of TNFR-I was observed in the RA patients (mean ± SD = 2.1289 ± 0.8117) as compared to the healthy controls (1.398 ± 0.5428, mean ± SD, Figure 2). However, we did not find an altered expression of TNFR-II gene in the PBMCs of the controls/cases in our cohort. The level of the gene expression in the controls (mean ± SD = 1 ± 0) was similar to that in the RA patients (mean ± SD = 1 ± 0) without any statistical significance (P = .692).

Statistical analysis

All data presented represent the mean and standard error (SE) for n determinations. Data analyses were performed using the World Wide Web available software. The density of PCR product for each sample was measured and the relative density mean (the value of the intensity of PCR product divided by the intensity for G3PDH) was calculated. All pairwise multiple comparisons were made using the Student t-test. The two tailed P values equal to or less than 0.05 were considered significant. Means ± SD (standard deviation) of the raw data used for normalization is presented in the results.

RESULTS

Expression of genes involved in the TNF-α mediated signaling pathway

We analyzed the constitutive expression of the genes that are involved in TNF-α mediated signaling in PBMCs of 30 normal healthy controls and 27 RA patients. We observed the following significant differences in the gene expression profile of the RA patients in comparison to the healthy controls.

Expression of TNF-α, TNFR-I, and TNFR-II genes

PBMCs from RA patients revealed a stronger expression of TNF-α and TNFR-I mRNA than those from the controls (Figure 2). There was a statistically significant difference (P < 0) between the expression of TNF-α in the RA patients (mean ± SD = 1.607 ± 0.39) with the healthy controls (mean ± SD = 1.0215 ± 0.224). An increase (P < .0003) in the expression of TNFR-I was observed in the RA patients (mean ± SD = 2.1289 ± 0.8117) as compared to the healthy controls (1.398 ± 0.5428, mean ± SD, Figure 2). However, we did not find an altered expression of TNFR-II gene in the PBMCs of the controls/cases in our cohort. The level of the gene expression in the controls (mean ± SD = 1 ± 0) was similar to that in the RA patients (mean ± SD = 1 ± 0) without any statistical significance (P = .692).

Statistical analysis

All data presented represent the mean and standard error (SE) for n determinations. Data analyses were performed using the World Wide Web available software. The density of PCR product for each sample was measured and the relative density mean (the value of the intensity of PCR product divided by the intensity for G3PDH) was calculated. All pairwise multiple comparisons were made using the Student t-test. The two tailed P values equal to or less than 0.05 were considered significant. Means ± SD (standard deviation) of the raw data used for normalization is presented in the results.

RESULTS

Expression of genes involved in the TNF-α mediated signaling pathway

We analyzed the constitutive expression of the genes that are involved in TNF-α mediated signaling in PBMCs of 30 normal healthy controls and 27 RA patients. We observed the following significant differences in the gene expression profile of the RA patients in comparison to the healthy controls.

Expression of TNF-α, TNFR-I, and TNFR-II genes

PBMCs from RA patients revealed a stronger expression of TNF-α and TNFR-I mRNA than those from the controls (Figure 2). There was a statistically significant difference (P < 0) between the expression of TNF-α in the RA patients (mean ± SD = 1.607 ± 0.39) with the healthy controls (mean ± SD = 1.0215 ± 0.224). An increase (P < .0003) in the expression of TNFR-I was observed in the RA patients (mean ± SD = 2.1289 ± 0.8117) as compared to the healthy controls (1.398 ± 0.5428, mean ± SD, Figure 2). However, we did not find an altered expression of TNFR-II gene in the PBMCs of the controls/cases in our cohort. The level of the gene expression in the controls (mean ± SD = 1 ± 0) was similar to that in the RA patients (mean ± SD = 1 ± 0) without any statistical significance (P = .692).
4 Mediators of Inflammation

Expression of TRADD and FADD genes

The representative RT-PCR gels demonstrating the expression of TRADD and FADD genes from control and RA cases are shown in Figure 3. As evident, there was a statistically significant increase in the expression of TRADD gene ($P < 0$) in the RA patients (mean ± SD = 1.919 ± 0.581) in comparison to the normal healthy controls (mean ± SD = 1.312 ± 0.2885). However, the FADD gene was observed to be equally expressed in both the cases and the controls (patients mean ± SD = 1.497 ± 0.782, controls mean ± SD = 1.7816 ± 0.360).

Expression of RIP and TRAF-2 genes

On analyzing the expression of RIP and TRAF-2 genes in the controls and RA patients (Figure 4), we observed an increase in the expression of both the RIP ($P = 0.0123$) and TRAF-2 genes ($P = 0$) in RA patients (RIP: mean ± SD = 2.9799 ± 1.4946, TRAF2: mean ± SD = 1.942 ± 0.564) as compared to the healthy controls (RIP: mean ± SD = 2.0966 ± 0.9343, TRAF2: mean ± SD = 1.1944 ± 0.582).

DISCUSSION

Rheumatoid arthritis (RA), an autoimmune disease, is characterized by chronic inflammatory symptoms leading to damage of synovial tissue and joints. Proinflammatory cytokines like TNF-α reportedly contributes to the pathogenesis of rheumatoid arthritis [17]. In support of such reports we also observed an overexpression of TNF-α gene in the PBMCs of RA patients as compared to the healthy controls. TNF-α is associated with various cell signaling systems via two types of cell surface receptors, TNFR-I (p55) and TNFR-II (p75) [8, 10]. TNFR-I is involved in both proapoptotic and antiapoptotic signaling via the interaction with TRADD-FADD and TRADD-RIP-TRAF-2, respectively, [10]. Both TNFR-I and Fas-mediated apoptotic pathways use FADD as a common conduit [18] for the activation of apoptotic signaling. In contrast, TNFR-II is involved in an antiapoptotic effect of TNF-α via TRAF-2 [8].
The present study, for the first time, demonstrates that the PBMCs of RA patients showed an overexpression of TNFR-I and TRADD genes in comparison to the healthy controls; however, only a mild increase in TNFR-II expression was observed. Overexpression of TRADD results in apoptotic cell death via TNF-α induction of caspases as reported in many cell lines [19]. We observed a similar expression of the FADD gene among the RA patients and the healthy controls. This result indicates that the TNF-α/TRADD/FADD induced apoptotic pathway is not being followed in the PBMCs of the RA patients.

We observed a constitutive expression of TNFR-II gene in both the controls and the RA patients without any statistical significance. This nullifies any significant overexpression of the TNFRII mediated proliferative/antiapoptotic pathway in the RA patients. However the TRAF-2 and RIP genes in the PBMCs were significantly over expressed among the RA patients. This demonstrates a significant overexpression of the antiapoptotic pathway in the PBMCs of the RA patients in contrast to the healthy individuals.

Our observations of increased TRAF-2/RIP expression in PBMCs suggest that an increased TRAF-2/RIP may result in TNF-α-induced proliferation via NF-kB-dependent pathway.

In conclusion, PBMCs of the RA patients are observed to be more susceptible to TNF-α induced proliferation as compared to control subjects and are associated with a decreased expression of molecules (FADD) involved in apoptotic pathways. Increased expression of TNF-α in the PBMCs and increased susceptibility of these cells to TNF-α induced antiapoptosis may play a role in the pathogenesis of the disease.

The present study therefore supports the notion that the changes in the expression of TNF-α associated downstream molecules are more complicated than the expression of TNF-α/TNF receptors. This is probably caused by the complex regulatory mechanisms including cross talks with other signaling pathways that function in association with TNF-α mediated signaling pathways.

ACKNOWLEDGMENTS

The authors wish to thank the Council of Scientific and Industrial Research, India, for the financial assistance and Mr. A. N. Shirkey of Army Hospital, Department of Rheumatology, for his constant support during collection of blood samples from the patients.

REFERENCES


